217 related articles for article (PubMed ID: 32443328)
1. Clinicopathological characteristics of primary central nervous system lymphoma with low 18F-fludeoxyglucose uptake on brain positron emission tomography.
Kim HO; Kim JS; Kim SO; Chae SY; Oh SJ; Seo M; Lee SH; Oh JS; Ryu JS; Huh JR; Kim JH
Medicine (Baltimore); 2020 May; 99(20):e20140. PubMed ID: 32443328
[TBL] [Abstract][Full Text] [Related]
2.
Zhou W; Wen J; Hua F; Xu W; Lu X; Yin B; Geng D; Guan Y
Eur J Radiol; 2018 Jul; 104():26-32. PubMed ID: 29857862
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma.
Kawai N; Miyake K; Yamamoto Y; Nishiyama Y; Tamiya T
Biomed Res Int; 2013; 2013():247152. PubMed ID: 23844359
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma.
Yamaguchi S; Hirata K; Kobayashi H; Shiga T; Manabe O; Kobayashi K; Motegi H; Terasaka S; Houkin K
Ann Nucl Med; 2014 Aug; 28(7):603-9. PubMed ID: 24743915
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: A systematic review and meta-analysis.
Zou Y; Tong J; Leng H; Jiang J; Pan M; Chen Z
Oncotarget; 2017 Jun; 8(25):41518-41528. PubMed ID: 28514747
[TBL] [Abstract][Full Text] [Related]
6. The combination of 13N-ammonia and 18F-FDG in predicting primary central nervous system lymphomas in immunocompetent patients.
Shi X; Zhang X; Yi C; Wang X; Chen Z; Zhang B
Clin Nucl Med; 2013 Feb; 38(2):98-102. PubMed ID: 23334122
[TBL] [Abstract][Full Text] [Related]
7. [Usefulness and limitation of FDG-PET in the diagnosis of primary central nervous system lymphoma].
Kawai N; Miyake K; Okada M; Yamamoto Y; Nishiyama Y; Tamiya T
No Shinkei Geka; 2013 Feb; 41(2):117-26. PubMed ID: 23378387
[TBL] [Abstract][Full Text] [Related]
8. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
9. Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings.
Kawai N; Okubo S; Miyake K; Maeda Y; Yamamoto Y; Nishiyama Y; Tamiya T
Ann Nucl Med; 2010 Jun; 24(5):335-43. PubMed ID: 20379859
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of pretreatment 18F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment.
Kawai N; Zhen HN; Miyake K; Yamamaoto Y; Nishiyama Y; Tamiya T
J Neurooncol; 2010 Nov; 100(2):225-32. PubMed ID: 20390437
[TBL] [Abstract][Full Text] [Related]
11. What is the Best Preoperative Quantitative Indicator to Differentiate Primary Central Nervous System Lymphoma from Glioblastoma?
Inoue A; Matsumoto S; Ohnishi T; Miyazaki Y; Kinnami S; Kanno K; Honda T; Kurata M; Taniwaki M; Kusakabe K; Suehiro S; Yamashita D; Shigekawa S; Watanabe H; Kitazawa R; Kunieda T
World Neurosurg; 2023 Apr; 172():e517-e523. PubMed ID: 36690204
[TBL] [Abstract][Full Text] [Related]
12. Quantitative and Visual Characteristics of Primary Central Nervous System Lymphoma on
Liu D; Kong Z; Wang Y; Chen W; Wang Y; Chen W; Liu L; Dang Y; Ma W; Wang Y; Cheng X
Interdiscip Sci; 2019 Jun; 11(2):300-306. PubMed ID: 31264053
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of
Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Arai-Okuda H; Hatakeyama T; Miyake K; Nishiyama Y
J Neurooncol; 2024 Jan; 166(1):195-201. PubMed ID: 38160415
[TBL] [Abstract][Full Text] [Related]
14. Differentiating between Primary Central Nervous System Lymphoma and Glioblastoma: The Diagnostic Value of Combining
Hatakeyama J; Ono T; Takahashi M; Oda M; Shimizu H
Neurol Med Chir (Tokyo); 2021 Jun; 61(6):367-375. PubMed ID: 33967177
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma.
Kreher S; Jöhrens K; Strehlow F; Martus P; Borowiec K; Radke J; Heppner F; Roth P; Thiel E; Pietsch T; Weller M; Korfel A
Neuro Oncol; 2015 Jul; 17(7):1016-21. PubMed ID: 25817328
[TBL] [Abstract][Full Text] [Related]
16. Case report of an elderly woman with atypical imaging for primary central nervous system lymphoma who needed a brain biopsy for diagnosis.
Matsuzono K; Yagisawa T; Ohtani K; Ishishita Y; Yamaguchi T; Mashiko T; Ozawa T; Koide R; Tanaka R; Kawai K; Fujimoto S
J Int Med Res; 2021 Aug; 49(8):3000605211035197. PubMed ID: 34461767
[TBL] [Abstract][Full Text] [Related]
17. Utility of brain FDG-PET in primary CNS lymphoma.
Mohile NA; Deangelis LM; Abrey LE
Clin Adv Hematol Oncol; 2008 Nov; 6(11):818-20, 840. PubMed ID: 19194366
[TBL] [Abstract][Full Text] [Related]
18. The utility of body FDG PET in staging primary central nervous system lymphoma.
Mohile NA; Deangelis LM; Abrey LE
Neuro Oncol; 2008 Apr; 10(2):223-8. PubMed ID: 18287338
[TBL] [Abstract][Full Text] [Related]
19. Use of FDG-PET/CT for systemic assessment of suspected primary central nervous system lymphoma: a LOC study.
Bertaux M; Houillier C; Edeline V; Habert MO; Mokhtari K; Giron A; Bergeret S; Hoang-Xuan K; Cassoux N; Touitou V; Choquet S; Soussain C; Kas A
J Neurooncol; 2020 Jun; 148(2):343-352. PubMed ID: 32405997
[TBL] [Abstract][Full Text] [Related]
20. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up.
Palmedo H; Urbach H; Bender H; Schlegel U; Schmidt-Wolf IG; Matthies A; Linnebank M; Joe A; Bucerius J; Biersack HJ; Pels H
Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):164-8. PubMed ID: 16220304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
